Ionis Pharmaceuticals Management
Management criteria checks 2/4
Ionis Pharmaceuticals' CEO is Brett Monia, appointed in Jan 2020, has a tenure of 4.83 years. total yearly compensation is $12.50M, comprised of 7.7% salary and 92.3% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $5.92M. The average tenure of the management team and the board of directors is 4.8 years and 8.5 years respectively.
Key information
Brett Monia
Chief executive officer
US$12.5m
Total compensation
| CEO salary percentage | 7.7% |
| CEO tenure | 4.8yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.8yrs |
| Board average tenure | 8.5yrs |
Recent management updates
Recent updates
Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling
Oct 23There Is A Reason Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Price Is Undemanding
Aug 24
Ionis Pharmaceuticals: Harnessing RNA-Targeted Therapies For Long-Term Shareholder Value
Aug 11Health Check: How Prudently Does Ionis Pharmaceuticals (NASDAQ:IONS) Use Debt?
Jul 28Ionis: Tough Run For Share Price Belies Multiple Reasons For Optimism
May 28Analysts Have Made A Financial Statement On Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) First-Quarter Report
May 09Lacklustre Performance Is Driving Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Low P/S
Apr 14Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
Mar 18Ionis Pharmaceuticals 2023 Earnings Review: Short-Term Pain, Long-Term Gain
Feb 23Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Investors Are Less Pessimistic Than Expected
Dec 28Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Dec 07A Look At The Intrinsic Value Of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Nov 16Ionis Pharmaceuticals (NASDAQ:IONS) Has Debt But No Earnings; Should You Worry?
Aug 03Is Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?
May 05Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
Jan 20Ionis Pharmaceuticals Looks Good For The Long Term
Oct 19Ionis plans for new manufacturing site in California to support pipeline
Oct 13Ionis: 2 Drug Advancements With Potential Firsts
Aug 29Ionis Pharmaceuticals Q2 2022 Earnings Preview
Aug 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$359m |
| Jun 30 2024 | n/a | n/a | -US$366m |
| Mar 31 2024 | n/a | n/a | -US$385m |
| Dec 31 2023 | US$13m | US$961k | -US$366m |
| Sep 30 2023 | n/a | n/a | -US$409m |
| Jun 30 2023 | n/a | n/a | -US$309m |
| Mar 31 2023 | n/a | n/a | -US$329m |
| Dec 31 2022 | US$7m | US$825k | -US$270m |
| Sep 30 2022 | n/a | n/a | US$7m |
| Jun 30 2022 | n/a | n/a | -US$28m |
| Mar 31 2022 | n/a | n/a | -US$4m |
| Dec 31 2021 | US$13m | US$800k | -US$29m |
| Sep 30 2021 | n/a | n/a | -US$608m |
| Jun 30 2021 | n/a | n/a | -US$550m |
| Mar 31 2021 | n/a | n/a | -US$495m |
| Dec 31 2020 | US$11m | US$700k | -US$444m |
| Sep 30 2020 | n/a | n/a | US$94m |
| Jun 30 2020 | n/a | n/a | US$145m |
| Mar 31 2020 | n/a | n/a | US$169m |
| Dec 31 2019 | US$7m | US$528k | US$281m |
| Sep 30 2019 | n/a | n/a | US$433m |
| Jun 30 2019 | n/a | n/a | US$402m |
| Mar 31 2019 | n/a | n/a | US$366m |
| Dec 31 2018 | US$4m | US$508k | US$277m |
| Sep 30 2018 | n/a | n/a | -US$41m |
| Jun 30 2018 | n/a | n/a | -US$38m |
| Mar 31 2018 | n/a | n/a | US$9m |
| Dec 31 2017 | US$2m | US$443k | US$19m |
Compensation vs Market: Brett's total compensation ($USD12.50M) is above average for companies of similar size in the US market ($USD7.78M).
Compensation vs Earnings: Brett's compensation has increased whilst the company is unprofitable.
CEO
Brett Monia (63 yo)
4.8yrs
Tenure
US$12,500,023
Compensation
Dr. Brett P. Monia, Ph.D. is a Founder of Ionis Pharmaceuticals, Inc. in 1989 and has been Chief Executive Officer since January 2020. He has extensive experience across a range of therapeutic areas, inclu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 4.8yrs | US$12.50m | 0.11% $ 5.9m | |
| Executive VP of Finance & CFO | 11.8yrs | US$2.89m | 0.059% $ 3.3m | |
| Director | 6.8yrs | US$538.04k | 0.055% $ 3.1m | |
| Executive VP & Chief Development Officer | 16.3yrs | US$2.56m | 0.054% $ 3.0m | |
| Executive Vice President of Research | 4.8yrs | US$2.56m | 0.021% $ 1.2m | |
| Chief Accounting Officer & Senior VP | 4.8yrs | no data | no data | |
| Executive VP & Chief Scientific Officer | 4.8yrs | US$958.87k | 0.050% $ 2.8m | |
| Senior Vice President of Investor Relations | no data | no data | no data | |
| Executive VP | 11.8yrs | US$3.92m | 0.031% $ 1.7m | |
| Vice President of Corporate Communications | less than a year | no data | no data | |
| Senior Vice President of Human Resources | 4.8yrs | no data | 0.0050% $ 279.8k | |
| Scientific Advisor | 3.4yrs | US$2.28m | no data |
4.8yrs
Average Tenure
64.5yo
Average Age
Experienced Management: IONS's management team is considered experienced (4.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 5.7yrs | US$12.50m | 0.11% $ 5.9m | |
| Director | 24.2yrs | US$538.04k | 0.055% $ 3.1m | |
| Independent Director | 5.4yrs | US$540.04k | 0.027% $ 1.5m | |
| Independent Director | 18.9yrs | US$542.04k | 0.010% $ 581.9k | |
| Lead Independent Director | 30.8yrs | US$598.04k | 0.084% $ 4.7m | |
| Independent Director | 6.2yrs | US$528.04k | 0.020% $ 1.1m | |
| Independent Director | 22.5yrs | US$548.04k | 0.096% $ 5.4m | |
| Independent Chairman of the Board | 10.8yrs | US$568.04k | 0.020% $ 1.1m | |
| Independent Director | 3.4yrs | US$530.04k | 0.010% $ 555.7k | |
| Independent Director | less than a year | US$363.05k | no data |
8.5yrs
Average Tenure
70yo
Average Age
Experienced Board: IONS's board of directors are considered experienced (8.5 years average tenure).